drugset
drugset / Trial / NCT07187778

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

NCT07187778 ↗

Phase 2 Recruiting 10 enrolled M.D. Anderson Cancer Center Merck Sharp & Dohme LLC · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To learn if belzutifan alone, pembrolizumab alone, or belzutifan and pembrolizumab in combination given before a total or partial nephrectomy (surgery to remove all or part of a kidney) can help to control locally advanced ccRCC.

Timeline

Start
2025-12-19
Primary completion
2027-07-19
Completion
2029-07-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Belzutifan Small molecule — Oral
Subject Pembrolizumab Monoclonal antibody — Oral

Indications

clear cell renal carcinoma